Streetbeat News

Products Services

ABBV

GMAB

Genmab and AbbVie announced that the FDA has granted priority review for their supplemental Biologics License Application for epcoritamab-bysp, aimed at treating relapsed/refractory follicular lymphoma after two or more lines of systemic therapy.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:47 pm

TGTX

TG Therapeutics announced the issuance of three additional US patents for Briumvi, a treatment for relapsing forms of multiple sclerosis, which can now be administered in a one-hour infusion following the starting dose. This development could enhance the drug's marketability and patient convenience, potentially impacting TG Therapeutics' market position positively.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:35 pm

CMND

Clearmind Medicine has submitted three additional international patent applications for innovative compounds related to MDMA, Ibogaine, and Ketamine. This move signifies the company's ongoing efforts to expand its intellectual property portfolio in the psychedelic medicine space.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:30 pm

IINN

Inspira Technologies OXY B.H.N. Ltd. (IINN) is on track to receive its first FDA 510(k) clearance for the INSPIRA ART100 in H1 2024, with plans for more submissions. It has secured three US patents and signed $546M in distribution agreements, pending regulatory approvals.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:15 pm

MNPR

Monopar Therapeutics announced Professor Rodney Hicks as the lead investigator for the Phase 1 dosimetry clinical trial of MNPR-101-Zr in advanced cancer patients. The trial will take place at the Melbourne Theranostic Innovation Centre using the Siemens Biograph Vision Quadra PET/CT scanner.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:13 pm

ACXP

Acurx Pharmaceuticals announced that the FDA has granted an end of Phase 2 meeting for its drug, Ibezapolstat, aimed at treating C. difficile infection. Additionally, the European Medicines Agency has granted SME (Small and Medium-sized Enterprises) designation for the development of Ibezapolstat in the EU. This marks significant regulatory milestones for Acurx, potentially accelerating the drug's development and approval process in both the US and Europe.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:11 pm

APPS

CAMP

FIVN

The article highlights the top 3 oversold tech stocks in the information technology sector, suggesting they may be undervalued opportunities for investors. These include Five9, Inc. (FIVN), CalAmp Corp. (CAMP), and Digital Turbine, Inc. (APPS), each with an RSI below 30, indicating they are oversold. Recent financial results and market actions are discussed for each company, providing insight into their current stock performance and potential for short-term recovery.

Portfolio Pulse from Avi Kapoor

February 27, 2024 | 12:10 pm

ACXP

Acurx Pharmaceuticals announced that the FDA has granted an end of Phase 2 meeting for its drug, Ibezapolstat, aimed at treating C. difficile infection. Additionally, the European Medicines Agency has granted SME (Small and Medium-sized Enterprises) designation for the development of Ibezapolstat in the EU. This marks significant regulatory milestones for Acurx in advancing the drug's development and potential market entry in both the US and Europe.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:10 pm

SPY

Ark Invest's Chief Futurist Brett Winton predicts U.S. real GDP growth could average 7% annually in the current business cycle, driven by transformative technologies like AI, blockchain, and robotics. This forecast surpasses the consensus view and historical growth rates, drawing parallels with past technological revolutions. The SPDR S&P 500 ETF Trust (SPY) saw a slight increase in premarket trading.

Portfolio Pulse from Shanthi Rexaline

February 27, 2024 | 12:04 pm

ELF

E.L.F. Beauty, Inc. (NYSE:ELF) has opened its first European office in London to expand its international business, following a 119% year-over-year growth in international net sales. The company entered the Italian market in late 2023 and is focusing on color cosmetics, skincare, and international markets for growth. Analyst Korinne Wolfmeyer of Piper Sandler has reiterated an Overweight rating on ELF, raising the forecast to $225 from $212, citing expansion prospects in India and Western Europe. E.L.F. Beauty has also raised its fiscal year 2024 earnings per share and revenue guidance.

Portfolio Pulse from Nabaparna Bhattacharya

February 27, 2024 | 11:57 am